Experts speculate on why Eli Lilly's Alzheimer's drug failed

08/17/2010 | Forbes

The recent halt of a study involving Eli Lilly's experimental Alzheimer's disease drug, a compound known as a gamma secretase inhibitor, has some experts speculating on what could have went wrong with the drug. The drug was designed to target the brain's amyloid protein, which is thought to accelerate the development of the disease. One angle being considered is that amyloid is really an effect of the disease, not its cause, and targeting it could make the disease worse.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
PacificSource
Bend, OR
Clinical Appeals RN
MJHS
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ